Please assess the completion status of the following clinical trial:

Trial Title: Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of type 2 diabetes~* Participants between the ages of 30 and 80~Exclusion Criteria:~1. Presence of type 1 diabetes~2. Presence of renal insufficiency or pulmonary disease~3. Presence of clinically significant neuropathy that is clearly of non-diabetic origin~4. Amputations of lower extremities or presence of foot ulcers~5. Major macrovascular events such as myocardial infarction or stroke within the past 3 months~6. Uncontrolled or untreated hypothyroidism~7. Abnormalities of liver function defined as any liver enzymes (AST, ALT, SGPT, SGOT) greater than 3 times the upper limit of normal~8. Other serious medical conditions which, in the opinion of the investigator, would compromise the subject's participation in the study~9. Stable use (\> 3 months) of antioxidant supplements or drugs known to affect oxidative stress and PDN~10. Allergy to oxybutynin or other ingredients in Gelnique 3%~11. Pregnancy or breastfeeding~13) History of alcohol abuse in the last year 14) Urinary retention or an enlarged prostate 15) Uncontrolled glaucoma 16) Gastric retention or gastroparesis (hard to digest food) 17) Currently taking other medicines to treat overactive bladder (Anticholinergics)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 3% oxybutynin (Type: ACTIVE_COMPARATOR): Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the active drug arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
- Placebo (Type: PLACEBO_COMPARATOR): Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the placebo group arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,

Based on this trial design, predict the completion outcome and termination type (if applicable).